Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutc...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 6,287,878 shares of its common stock to the public at $16.50 per share...
Shares of Assembly Biosciences (NASDAQ: ASMB) , a clinical-stage biopharmaceutical company, were on the move after the company priced an upcoming share offering. Investors encouraged by the offering price drove the stock 29.2% higher as of 1:33 p.m. EST on Thursday. After losing $70.6 m...
Gainers: Amneal Pharmaceuticals (NYSE: AMRX ) +49% . More news on: Amneal Pharmaceuticals, Inc., Diebold Nixdorf, Incorporated, Assembly Biosciences, Inc., Stocks on the move, Read more ...
Assembly Biosciences (NASDAQ: ASMB ) has priced its public offering of 5,151,515 common shares at $16.50 per share. In addition, and in lieu of common stock, the Company is offering pre-funded warrants to purchase up to 2,424,242 common shares at $16.499 per pre-funded warrant. More news...
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition, and in ...
Gainers: AMRS +11.7% . GGB +4.9% . EVBG +4.3% . FREQ +2.8% . ACC +1.9% . More news on: Amyris, Inc., Gerdau S.A., Everbridge, Inc., Stocks on the move, , News on ETFs Read more ...
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Asse...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...